Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Equity Average (2018 - 2025)

Historic Equity Average for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Q3 2025 value amounting to $1.1 billion.

  • Crinetics Pharmaceuticals' Equity Average rose 3485.83% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 3485.83%. This contributed to the annual value of $932.0 million for FY2024, which is 11789.07% up from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Equity Average is $1.1 billion, which was up 3485.83% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Equity Average ranged from a high of $1.3 billion in Q1 2025 and a low of $159.2 million during Q1 2021
  • In the last 5 years, Crinetics Pharmaceuticals' Equity Average had a median value of $368.8 million in 2022 and averaged $566.5 million.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Equity Average crashed by 2245.52% in 2023, and later soared by 21915.22% in 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' Equity Average (Quarter) stood at $262.8 million in 2021, then increased by 27.05% to $333.8 million in 2022, then surged by 62.78% to $543.4 million in 2023, then soared by 98.53% to $1.1 billion in 2024, then rose by 3.98% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $1.2 billion for Q2 2025, and $1.3 billion during Q1 2025.